ICOSL Stimulation by ICOS-Fc Accelerates Cutaneous Wound Healing In Vivo.
ICOS:ICOSL system
reparative macrophages
wound healing
Journal
International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791
Informations de publication
Date de publication:
01 Jul 2022
01 Jul 2022
Historique:
received:
01
06
2022
revised:
29
06
2022
accepted:
30
06
2022
entrez:
9
7
2022
pubmed:
10
7
2022
medline:
14
7
2022
Statut:
epublish
Résumé
ICOS and its ligand ICOSL are immune receptors whose interaction triggers bidirectional signals that modulate the immune response and tissue repair. The aim of this study was to assess the in vivo effects of ICOSL triggering by ICOS-Fc, a recombinant soluble form of ICOS, on skin wound healing. The effect of human ICOS-Fc on wound healing was assessed, in vitro, and, in vivo, by skin wound healing assay using ICOS We show that, in wild type mice, treatment with ICOS-Fc improves wound healing, promotes angiogenesis, preceded by upregulation of IL-6 and VEGF expression; increases the number of fibroblasts and T cells, whereas it reduces that of neutrophils; and increases the number of M2 vs. M1 macrophages. Fittingly, ICOS-Fc enhanced M2 macrophage migration, while it hampered that of M1 macrophages. ICOS These data show that the ICOS/ICOSL network cooperates in tissue repair, and that triggering of ICOSL by ICOS-Fc improves cutaneous wound healing by increasing angiogenesis and recruitment of reparative macrophages.
Sections du résumé
BACKGROUND
BACKGROUND
ICOS and its ligand ICOSL are immune receptors whose interaction triggers bidirectional signals that modulate the immune response and tissue repair.
AIM
OBJECTIVE
The aim of this study was to assess the in vivo effects of ICOSL triggering by ICOS-Fc, a recombinant soluble form of ICOS, on skin wound healing.
METHODS
METHODS
The effect of human ICOS-Fc on wound healing was assessed, in vitro, and, in vivo, by skin wound healing assay using ICOS
RESULTS
RESULTS
We show that, in wild type mice, treatment with ICOS-Fc improves wound healing, promotes angiogenesis, preceded by upregulation of IL-6 and VEGF expression; increases the number of fibroblasts and T cells, whereas it reduces that of neutrophils; and increases the number of M2 vs. M1 macrophages. Fittingly, ICOS-Fc enhanced M2 macrophage migration, while it hampered that of M1 macrophages. ICOS
CONCLUSION
CONCLUSIONS
These data show that the ICOS/ICOSL network cooperates in tissue repair, and that triggering of ICOSL by ICOS-Fc improves cutaneous wound healing by increasing angiogenesis and recruitment of reparative macrophages.
Identifiants
pubmed: 35806368
pii: ijms23137363
doi: 10.3390/ijms23137363
pmc: PMC9266942
pii:
doi:
Substances chimiques
Icos protein, mouse
0
Icosl protein, mouse
0
Immunoglobulin Fc Fragments
0
Inducible T-Cell Co-Stimulator Ligand
0
Inducible T-Cell Co-Stimulator Protein
0
Recombinant Proteins
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Italian Association for Cancer Research
ID : IG 20714
Organisme : Fondazione Cariplo
ID : (2017-0535)
Organisme : University of Turin fund
ID : (DIAC_RILO_21)
Références
J Immunol. 2013 Feb 1;190(3):1125-34
pubmed: 23275603
Front Cell Dev Biol. 2020 Jul 17;8:636
pubmed: 32850791
Front Immunol. 2020 Aug 28;11:2104
pubmed: 32983168
Front Immunol. 2018 Nov 15;9:2650
pubmed: 30524429
Nature. 1999 Dec 16;402(6763):827-32
pubmed: 10617205
J Immunol. 2014 May 15;192(10):4921-31
pubmed: 24729612
Clin Cosmet Investig Dermatol. 2014 Nov 06;7:301-11
pubmed: 25395868
Biomedicines. 2021 Dec 27;10(1):
pubmed: 35052731
Commun Biol. 2020 Oct 26;3(1):615
pubmed: 33106594
J Immunol. 2010 Oct 1;185(7):3970-9
pubmed: 20817864
Am J Pathol. 2011 Nov;179(5):2360-9
pubmed: 21925472
N Engl J Med. 1999 Sep 2;341(10):738-46
pubmed: 10471461
J Exp Med. 2008 Jan 21;205(1):43-51
pubmed: 18180311
J Burn Care Res. 2012 May-Jun;33(3):311-8
pubmed: 22561306
Biomedicines. 2020 Apr 30;8(5):
pubmed: 32365896
Br J Haematol. 2022 Mar;196(6):1369-1380
pubmed: 34954822
Nat Rev Immunol. 2002 Feb;2(2):116-26
pubmed: 11910893
J Immunol. 2000 May 1;164(9):4689-96
pubmed: 10779774
J Cell Biol. 2018 Dec 3;217(12):4314-4330
pubmed: 30389720
J Immunol. 2016 Nov 15;197(10):3905-3916
pubmed: 27798154
Cell Mol Life Sci. 2009 Sep;66(18):3067-80
pubmed: 19603141
Front Immunol. 2021 Dec 03;12:786680
pubmed: 34925367
J Control Release. 2020 Apr 10;320:112-124
pubmed: 31962094